Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
19.76
-0.33 (-1.64%)
Dec 5, 2025, 4:00 PM EST - Market closed
Immunome Revenue
Immunome had revenue of $9.68M in the twelve months ending September 30, 2025, down -4.44% year-over-year. In the year 2024, Immunome had annual revenue of $9.04M, down -35.50%.
Revenue (ttm)
$9.68M
Revenue Growth
-4.44%
P/S Ratio
161.95
Revenue / Employee
$82,025
Employees
118
Market Cap
1.81B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMNM News
- 1 day ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Immunome to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire
- 6 weeks ago - Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance - Business Wire
- 2 months ago - Infinimmune Announces Research Collaboration with Immunome - Business Wire
- 3 months ago - Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 4 months ago - Immunome: SpringWorks Buyout Informs The Potential Upside Here - Seeking Alpha